COMMUNIQUÉS West-GlobeNewswire

Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
06/02/2026
Allschwil, Switzerland – February 06, 2026 Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker and renal findings [...]
Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026
06/02/2026
An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth eligibility considerations, [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
05/02/2026
CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
05/02/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Agomab Announces Pricing of Initial Public Offering
06/02/2026
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology [...]
Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05/02/2026
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2026
05/02/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
05/02/2026
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the [...]
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
05/02/2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th [...]
His Choice Health Announces Opening of New Charlotte Clinic, Expanding Access to Trusted, Patient-Centered Men’s Health Care
06/02/2026
Regional Growth Following Raleigh–Durham Brand Unification CHARLOTTE, NC, Feb. 05, 2026 (GLOBE NEWSWIRE) -- His Choice Health today announced the upcoming opening of its newest clinic in Charlotte, targeted late [...]
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
05/02/2026
NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra- [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05/02/2026
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Renaissance Recovery’s Award-Winning Drug and Alcohol Rehab Center Launches New 10,000 Sq. Ft. Expansion in Nashville, Tennessee
05/02/2026
NASHVILLE, Tenn., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Renaissance Recovery, a District Behavioral Health Group (DBH) company, announced today the opening of its newest expansion in Nashville, Tennessee. As an award- [...]
SpyGlass Pharma Announces Pricing of Initial Public Offering
06/02/2026
ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375 [...]
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
05/02/2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial [...]
PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026
06/02/2026
An informational overview examining compounded semaglutide vs FDA-approved GLP-1 medications, telehealth platform evaluation criteria, and what consumers consider when researching prescription weight management [...]

Pages